Indication

Androgen-Insensitive Prostatic Cancer

1 clinical trial

2 products

Product

Vobramitamab Duocarmazine

Clinical trial

A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

Status: Active (not recruiting), Estimated PCD: 2027-05-01

Product